iHuman (IH) director Chi Hanfeng reports options on 54,000 Class A shares

Rhea-AI Filing Summary

iHuman Inc. director Chi Hanfeng has filed an initial ownership report showing holdings of stock options linked to the company’s Class A ordinary shares. The filing lists options covering 27,000 underlying shares at an exercise price of $0.0500 per share, expiring on November 30, 2030, and another block covering 27,000 underlying shares at the same exercise price, expiring on December 15, 2032.

According to the footnotes, the 2030 options were granted on November 30, 2020 and vested over three years, while the 2032 options were granted on December 15, 2022 and vest in equal annual installments over four years. All holdings are reported as directly owned.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Chi Hanfeng

(Last) (First) (Middle)

TOWER 306, NO.86 BEIYUAN ROAD

CHAOYANG DISTRICT

(Street)

BEIJING 100101

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
iHuman Inc. [ IH ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	(1)	11/30/2030	Class A ordinary shares	27,000	$0.05	D
Options	(2)	12/15/2032	Class A ordinary shares	27,000	$0.05	D

Explanation of Responses:

1. These options were granted on November 30, 2020 and vested over a three-year period, with 33.33% of the options vesting on October 8, 2021, 33.33% on October 8, 2022, and the remaining 33.34% on October 8, 2023.

2. These options were granted on December 15, 2022 and vest in equal installments over a four-year period, with 25% of the options vest on each anniversary after the grant date.

	/s/ Hanfeng Chi	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the iHuman (IH) Form 3 filing by Chi Hanfeng report?

The Form 3 reports that director Chi Hanfeng holds stock options over iHuman Class A ordinary shares. It details two option grants, their exercise price of $0.0500 per share, vesting schedules, and expirations in 2030 and 2032, all shown as directly owned.

How many iHuman (IH) shares are covered by Chi Hanfeng’s reported options?

The filing shows options linked to a total of 54,000 iHuman Class A ordinary shares. One grant covers 27,000 underlying shares expiring in 2030, and another covers 27,000 underlying shares expiring in 2032, both with the same exercise price.

What are the exercise prices and expiration dates of Chi Hanfeng’s iHuman options?

Both option grants carry an exercise price of $0.0500 per share. One grant, over 27,000 underlying shares, expires on November 30, 2030, while the second, also for 27,000 underlying shares, expires on December 15, 2032, according to the filing.

How do Chi Hanfeng’s iHuman option grants vest according to the Form 3 footnotes?

The November 30, 2020 grant vested over three years, with 33.33% vesting on each of October 8, 2021 and October 8, 2022, and 33.34% on October 8, 2023. The December 15, 2022 grant vests in four equal annual installments after the grant date.

Are Chi Hanfeng’s iHuman (IH) option holdings direct or indirect?

The filing classifies all reported option positions as directly held. The ownership code is shown as “D,” and no footnotes indicate that the options are controlled through a separate trust, partnership, or other indirect ownership vehicle.